Table of contents
In this issue
p631 | doi:10.1038/nrd1484
Editorial: Hoping for the mother of all mergers
p633 | doi:10.1038/nrd1482
News and Analysis
News
Calls for full disclosure of clinical trials
p635 | doi:10.1038/nrd1485
News in Brief
News
Mid-year at the FDA highlights permanent problem
p637 | doi:10.1038/nrd1486
Patent watch
Lack of intracellular definition
p638 | doi:10.1038/nrd1478
Patent watch
All-elements rule
p638 | doi:10.1038/nrd1489
Patent watch
Antitrust case can proceed
p638 | doi:10.1038/nrd1490
Patent primer
Reach-through claims: how far a reach?
p639 | doi:10.1038/nrd1491
An Audience With
Francis S. Collins
p640 | doi:10.1038/nrd1488
From the analyst's couch
Statin switch to OTC
p641 | doi:10.1038/nrd1471
Fresh from the Pipeline
Tiotropium bromide
p643 | doi:10.1038/nrd1472
Research Highlights
Antiviral drugs: Third strike against HIV enzymes
p645 | doi:10.1038/nrd1480
Autoimmune diabetes: NKG2D receptor: a therapeutic target?
p646 | doi:10.1038/nrd1475
Anticancer drugs: Taking out the chaperone
p646 | doi:10.1038/nrd1476
Nuclear receptors: Growing concern for tamoxifen
p647 | doi:10.1038/nrd1474
Statins: Target audience
p648 | doi:10.1038/nrd1477
In brief
Sexual Dysfunction | Cancer | Multiple Sclerosis
p648 | doi:10.1038/nrd1479
Reviews
Article series: Case Histories
Case history
A new oral anticoagulant: the 50-year challenge
David Gustafsson, Ruth Bylund, Thomas Antonsson, Ingemar Nilsson, Jan-Erik Nyström, Ulf Eriksson, Ulf Bredberg & Ann-Catrine Teger-Nilsson
p649 | doi:10.1038/nrd1466
Fragment-based lead discovery
David C. Rees, Miles Congreve,, Christopher W. Murray & Robin Carr
p660 | doi:10.1038/nrd1467
Drug repositioning: identifying and developing new uses for existing drugs
Ted T. Ashburn & Karl B. Thor
p673 | doi:10.1038/nrd1468
Recombinant biologics for treatment of bleeding disorders
Paul Bishop & Jeff Lawson
p684 | doi:10.1038/nrd1443
Lipid metabolic enzymes: emerging drug targets for the treatment of obesity
Yuguang Shi & Paul Burn
p695 | doi:10.1038/nrd1469
Perspective
Opinion
Can the pharmaceutical industry reduce attrition rates?
Ismail Kola & John Landis
p711 | doi:10.1038/nrd1470
Careers and Recruitment
Career focus
Training academic chemists for industry
Simon Frantz
p716 | doi:10.1038/nrd1483
